Clinical Trial Update: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase III trial evaluating Zibotentan (ZD4054) in combination with docetaxel for metastatic castration-resistant prostate cancer has completed and posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Zibotentan (ZD4054) (Zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-05-31